Analysts’ Recent Ratings Changes for Prime Medicine (PRME)

Several analysts have recently updated their ratings and price targets for Prime Medicine (NASDAQ: PRME):

• 7/8/2026 – Prime Medicine had its “buy” rating reaffirmed by TD Cowen.
• 6/29/2026 – Prime Medicine was given a new $8.00 price target by New Street Research.
• 6/29/2026 – Prime Medicine was upgraded by HC Wainwright from “neutral” to “buy”. They now have a $8.00 price target on the stock.
• 6/22/2026 – Prime Medicine was given a new $6.00 price target by The Goldman Sachs Group, Inc..
• 6/22/2026 – Prime Medicine had its “market outperform” rating reaffirmed by Citigroup Inc..
• 6/3/2026 – Prime Medicine had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 5/13/2026 – Prime Medicine was downgraded by Wall Street Zen from “sell” to “strong sell”.

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.